

Biologics Safety Testing Market by Product & Service (Consumables, Instrument, Services), Test Type (Mycoplasma, Sterility, Endotoxin, Bioburden, Virus Safety), Application (Vaccines, mAbs, Cell & Gene Therapy, Blood Products) - Global Forecast to 2029

Market Report | 2024-05-13 | 387 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The biologics safety testing market is projected to reach USD 7.2 billion by 2029 from an estimated USD 4.2 billion in 2024, at a CAGR of 11.1% from 2024 to 2029. The growth of this market can be attributed to the increasing focus on the development and manufacturing of novel biologics. The rising demand for advanced therapies such as cell and gene therapies due to the growing rate of chronic diseases is propelling the growth of biologics safety testing. This trend is expected to drive the growth of the biologics safety testing market in the coming years.

"The monoclonal antibodies development and manufacturing segment accounted for the largest share of by application segment in 2023."

In 2023, the monoclonal antibodies development and manufacturing segment accounted for the largest share of the global biologics safety testing market by application. Growing investments and funding in the development of novel biotherapeutics and rising demand for biological therapies for the treatment of chronic diseases are promoting the segment's growth in the biologics safety testing market.

"The US has continued to dominate the biologics safety testing market from 2024 to 2029."

The US dominated the biologics safety testing market in North America in 2023. The US is the world's largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Also, US has strong healthcare infrastructure which drives the research and development in life sciences sector. Additionally, US has large number of biopharmaceutical companies; thus, increasing number of biopharmaceutical companies and growing research activities in biotechnology sector are propelling the market growth in US. Moreover, increasing approvals for biosimilars are also driving the growth of biologics safety testing market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 60% and Demand Side 40%
 - By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
 - By Region: North America - 40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
- List of Companies Profiled in the Report:

- Thermo Fisher Scientific Inc. (US)
- Merck KGaA (Germany)
- Lonza (Switzerland)
- FUJIFILM Corporation (Japan)
- Sartorius AG (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Charles River Laboratories (US)
- BIOMERIEUX (France)
- Maravai LifeSciences (US)
- WuXi AppTec (China)
- SGS Societe Generale de Surveillance SA. (Switzerland)
- Sotera Health (Nelson Laboratories, LLC) (US)
- Samsung Biologics (South Korea)
- GenScript (US)
- Agilent Technologies, Inc. (US)
- Syngene International Limited (India)
- Eurofins Scientific (Luxembourg)
- Laboratory Corporation of America Holdings (US)
- Bio-Rad Laboratories, Inc. (US)
- QIAGEN (Netherlands)
- Promega Corporation (US)
- Catalent, Inc (US)
- ASSOCIATES OF CAPE COD, INC. (US)
- Pacific BioLabs (US)
- Clean Biologics (France)
- PathoQuest (France)
- ARL Bio Pharma, Inc. (US)
- Frontage Labs (US)
- Creative Biogene (US)
- Advaxia Biologics (Italy)

Research Coverage:

This research report categorizes the biologics safety testing market by product & service (services (mycoplasma testing services, sterility testing services, endotoxin testing services, virus safety testing services, bioburden testing services, and other testing services), consumables, and instrument), test type (residual host-cell proteins & DNA detection tests, mycoplasma tests, sterility tests, endotoxin tests, virus safety tests, bioburden tests, other biologics safety tests), application (monoclonal antibodies development and manufacturing, vaccine development and manufacturing, cellular & gene therapy products development and manufacturing, blood & blood products development and manufacturing, other applications), end user (pharmaceutical & biotechnology companies, CROs and CDMOs, and academic & research institutes), and by region (North America, Europe, Asia

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biologics safety testing market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, services, solutions, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations and acquisitions, and recent developments associated with the biologics safety testing market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall biologics safety testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (growing development of mAbs and biosimilars, rising investments and fundings in biopharmaceutical industry, and stringent regulatory guidelines for biologics safety), restraints (ethical concern regarding animal testing), opportunities (growing opportunities in emerging economies, increasing focus on next generation therapeutics), and Challenges (high cost of biologics) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the biologics safety testing market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biologics safety testing market
- Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), FUJIFILM Corporation (Japan), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Charles River Laboratories (US), BIOMERIEUX (France), Maravai LifeSciences (US), WuXi AppTec (China), SGS Societe Generale de Surveillance SA. (Switzerland), Sotera Health (Nelson Laboratories, LLC) (US), Samsung Biologics (South Korea), GenScript (US), Agilent Technologies, Inc. (US), Syngene International Limited (India), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands), Promega Corporation (US), Catalent, Inc (US), ASSOCIATES OF CAPE COD, INC. (US), Pacific BioLabs (US), Clean Biologics (France), PathoQuest (France), ARL Bio Pharma, Inc. (US), Frontage Labs (US), Creative Biogene (US), Advaxia Biologics (Italy), among others in the market.

Table of Contents:

1□INTRODUCTION□	52
1.1□STUDY OBJECTIVES□	52
1.2□MARKET DEFINITION□	52
1.2.1□INCLUSIONS & EXCLUSIONS□	53
1.3□STUDY SCOPE□	53
1.3.1□MARKET SEGMENTATION□	54
1.3.2□REGIONS COVERED□	54
1.4□YEARS CONSIDERED□	55
1.5□CURRENCY CONSIDERED□	55
1.6□STAKEHOLDERS□	55
1.7□LIMITATIONS□	55
1.8□SUMMARY OF CHANGES□	56
1.9□RECESSION IMPACT□	58
2□RESEARCH METHODOLOGY□	59
2.1□RESEARCH DATA□	59
FIGURE 1□RESEARCH DESIGN□	59
2.1.1□SECONDARY DATA□	60

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.1.2	PRIMARY DATA	60
FIGURE 2	BIOLOGICS SAFETY TESTING MARKET: BREAKDOWN OF PRIMARIES	61
2.2	MARKET ESTIMATION METHODOLOGY	62
2.2.1	GLOBAL MARKET SIZE ESTIMATION (BOTTOM-UP APPROACH)	62
FIGURE 3	BIOLOGICS SAFETY TESTING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023	62
FIGURE 4	BIOLOGICS SAFETY TESTING MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023	63
FIGURE 5	REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC. (2023)	64
2.2.2	INSIGHTS FROM PRIMARY EXPERTS	65
FIGURE 6	MARKET SIZE VALIDATION FROM PRIMARY SOURCES	65
2.2.3	SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)	65
FIGURE 7	SEGMENTAL MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH	65
2.3	MARKET GROWTH RATE PROJECTIONS	66
FIGURE 8	BIOLOGICS SAFETY TESTING MARKET: CAGR PROJECTIONS	67
TABLE 1	IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS	67
2.4	DATA TRIANGULATION	69
FIGURE 9	DATA TRIANGULATION METHODOLOGY	69
2.5	RESEARCH ASSUMPTIONS	70
2.6	RISK ANALYSIS	70
2.7	RECESSION IMPACT ANALYSIS	70
3	EXECUTIVE SUMMARY	72
FIGURE 10	BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)	72
FIGURE 11	BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2024 VS. 2029 (USD MILLION)	73
FIGURE 12	BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)	73
FIGURE 13	BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)	74
FIGURE 14	GEOGRAPHICAL SNAPSHOT OF BIOLOGICS SAFETY TESTING MARKET	75
4	PREMIUM INSIGHTS	76
4.1	BIOLOGICS SAFETY TESTING MARKET OVERVIEW	76
FIGURE 15	INCREASING DEVELOPMENT OF MONOCLONAL ANTIBODIES AND BIOSIMILARS TO SUPPORT MARKET GROWTH	76
4.2	NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE AND COUNTRY (2023)	77
FIGURE 16	SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2023	77
4.3	BIOLOGICS SAFETY TESTING MARKET SHARE, BY APPLICATION, 2023	77
FIGURE 17	MONOCLONAL ANTIBODIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023	77
4.4	BIOLOGICS SAFETY TESTING MARKET SHARE, BY END USER, 2023	78
FIGURE 18	PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT DOMINATED MARKET IN 2023	78
4.5	BIOLOGICS SAFETY TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	78
FIGURE 19	ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD	78
5	MARKET OVERVIEW	79
5.1	INTRODUCTION	79
5.2	MARKET DYNAMICS	79
FIGURE 20	BIOLOGICS SAFETY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	79
TABLE 2	BIOLOGICS SAFETY TESTING MARKET: IMPACT ANALYSIS	80
5.2.1	DRIVERS	80
5.2.1.1	Development of mAbs and biosimilars	80
TABLE 3	LIST OF FDA-APPROVED BIOSIMILAR PRODUCTS, 2022-2024	81
FIGURE 21	NUMBER OF ANTIBODY THERAPEUTICS GRANTED A FIRST APPROVAL IN US OR EU, 2012-2023	81
5.2.1.2	Growing concerns over cell culture contamination	82

5.2.1.3	Rising investments in biopharmaceutical R&D	82
FIGURE 22	WORLDWIDE TOTAL PHARMACEUTICAL R&D SPEND, 2014-2028	83
TABLE 4	PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2020 VS. 2026 (USD BILLION)	83
5.2.1.4	Increasing demand for advanced therapy medicinal products (ATMPs)	84
TABLE 5	LIST OF APPROVED GENE THERAPIES, 2023-2024	84
5.2.1.5	Stringent regulatory requirements for biologics safety testing	84
5.2.2	RESTRAINTS	85
5.2.2.1	Ethical concerns related to animal testing	85
5.2.3	OPPORTUNITIES	85
5.2.3.1	Growth opportunities in emerging markets	85
5.2.3.2	Increasing outsourcing of biopharmaceutical activities to CROs	86
5.2.3.3	Rising focus on next-generation therapeutics	87
5.2.4	CHALLENGES	87
5.2.4.1	High cost of biologics	87
TABLE 6	PRICING OF ADVANCED THERAPIES	88
5.2.4.2	Challenges related to biologics complexity and heterogenicity	88
5.3	TECHNOLOGY ANALYSIS	88
5.3.1	KEY TECHNOLOGIES	88
5.3.1.1	Polymerase chain reaction (PCR)	88
TABLE 7	APPLICATIONS OF PCR IN BIOLOGICS SAFETY TESTING	89
5.3.1.2	Next-generation sequencing (NGS)	89
5.3.2	COMPLEMENTARY TECHNOLOGIES	90
5.3.2.1	Lab-on-a-chip (LOC) systems	90
5.3.2.2	High-content screening (HCS)	90
5.3.3	ADJACENT TECHNOLOGIES	90
5.3.3.1	Bioinformatics and computational biology	90
5.4	SUPPLY CHAIN ANALYSIS	91
FIGURE 23	BIOLOGICS SAFETY TESTING MARKET: SUPPLY CHAIN ANALYSIS	92
5.5	VALUE CHAIN ANALYSIS	92
FIGURE 24	BIOLOGICS SAFETY TESTING MARKET: VALUE CHAIN ANALYSIS	93
5.6	PRICING ANALYSIS	94
TABLE 8	AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT	94
TABLE 9	AVERAGE SELLING PRICE OF BIOLOGICS SAFETY TESTING PRODUCTS, BY REGION	95
5.7	ECOSYSTEM ANALYSIS	95
FIGURE 25	BIOLOGICS SAFETY TESTING MARKET: ECOSYSTEM ANALYSIS	96
5.7.1	RAW MATERIAL VENDORS IN BIOLOGICS SAFETY TESTING MARKET	97
TABLE 10	BIOLOGICS SAFETY TESTING MARKET: ROLE OF RAW MATERIAL VENDORS	97
5.7.2	PRODUCT VENDORS IN BIOLOGICS SAFETY TESTING MARKET	97
TABLE 11	BIOLOGICS SAFETY TESTING MARKET: ROLE OF PRODUCT VENDORS	97
5.7.3	SERVICE PROVIDERS IN BIOLOGICS SAFETY TESTING MARKET	97
TABLE 12	BIOLOGICS SAFETY TESTING MARKET: ROLE OF SERVICE PROVIDERS	98
5.7.4	END USERS IN BIOLOGICS SAFETY TESTING MARKET	98
TABLE 13	BIOLOGICS SAFETY TESTING MARKET: ROLE OF END USERS	98
5.7.5	REGULATORY BODIES GOVERNING BIOLOGICS SAFETY TESTING MARKET	98
TABLE 14	BIOLOGICS SAFETY TESTING MARKET: ROLE OF REGULATORY BODIES	99
5.8	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	99
FIGURE 26	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	99

5.9	PATENT ANALYSIS	100
5.9.1	METHODOLOGY	100
5.9.2	PATENTS FILED, BY DOCUMENT TYPE, 2014-2024	100
	TABLE 15 PATENTS FILED, 2014-2024	100
5.9.3	INNOVATION AND PATENT APPLICATIONS	100
	FIGURE 27 TOTAL NUMBER OF PATENTS GRANTED, 2014-2024	101
5.9.4	TOP APPLICANTS	101
	FIGURE 28 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2024	101
	TABLE 16 TOP 20 PATENT OWNERS IN BIOLOGICS SAFETY TESTING MARKET, 2014-2024	102
	TABLE 17 PATENTS IN BIOLOGICS SAFETY TESTING MARKET, 2024	103
5.10	KEY CONFERENCES & EVENTS	104
	TABLE 18 BIOLOGICS SAFETY TESTING MARKET: KEY CONFERENCES & EVENTS, 2024-2025	104
5.11	REGULATORY LANDSCAPE	105
5.11.1	INTRODUCTION	105
5.11.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	106
	TABLE 19 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	106
	TABLE 20 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	106
	TABLE 21 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	107
	TABLE 22 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	108
5.11.3	REGULATORY SCENARIO	109
	TABLE 23 BIOLOGICS SAFETY TESTING MARKET: REGULATORY GUIDELINES	109
5.12	PORTER'S FIVE FORCES ANALYSIS	111
	FIGURE 29 BIOLOGICS SAFETY TESTING MARKET: PORTER'S FIVE ANALYSIS	112
	TABLE 24 BIOLOGICS SAFETY TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS	112
5.12.1	THREAT OF NEW ENTRANTS	113
5.12.2	THREAT OF SUBSTITUTES	113
5.12.3	BARGAINING POWER OF SUPPLIERS	113
5.12.4	BARGAINING POWER OF BUYERS	113
5.12.5	INTENSITY OF COMPETITIVE RIVALRY	113
5.13	KEY STAKEHOLDERS & BUYING CRITERIA	114
5.13.1	KEY STAKEHOLDERS IN BUYING PROCESS	114
	FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOLOGICS SAFETY TESTING PRODUCTS	114
5.13.2	BUYING CRITERIA FOR BIOLOGICS SAFETY TESTING MARKET	115
	FIGURE 31 KEY BUYING CRITERIA FOR END USERS	115
	TABLE 25 BUYING CRITERIA FOR BIOLOGICS SAFETY TESTING PRODUCTS & SERVICES, BY END USER	115
5.14	INVESTMENT/FUNDING SCENARIO	116
6	BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE	117
6.1	INTRODUCTION	118
	TABLE 26 BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)	118
6.2	SERVICES	118
	TABLE 27 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)	119
	TABLE 28 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)	119
	TABLE 29 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	120
	TABLE 30 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	120
	TABLE 31 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	121
	TABLE 32 LATIN AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	121
	TABLE 33 MIDDLE EAST: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	121

TABLE 34 GCC COUNTRIES: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 122

6.2.1 MYCOPLASMA TESTING SERVICES 122

6.2.1.1 Increasing focus on development of biologics and biosimilars to support segmental growth 122

TABLE 35 MYCOPLASMA TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) 122

TABLE 36 NORTH AMERICA: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 123

TABLE 37 EUROPE: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 123

TABLE 38 ASIA PACIFIC: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 124

TABLE 39 LATIN AMERICA: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 124

TABLE 40 MIDDLE EAST: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 124

TABLE 41 GCC COUNTRIES: MYCOPLASMA TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 125

6.2.2 STERILITY TESTING SERVICES 125

6.2.2.1 Rising focus on development of biologics and biosimilars to drive demand for sterility testing services 125

TABLE 42 STERILITY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) 126

TABLE 43 NORTH AMERICA: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 126

TABLE 44 EUROPE: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 126

TABLE 45 ASIA PACIFIC: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 127

TABLE 46 LATIN AMERICA: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 127

TABLE 47 MIDDLE EAST: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 127

TABLE 48 GCC COUNTRIES: STERILITY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 128

6.2.3 ENDOTOXIN TESTING SERVICES 128

6.2.3.1 Stringent regulatory requirements to drive market 128

TABLE 49 ENDOTOXIN TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) 128

TABLE 50 NORTH AMERICA: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 129

TABLE 51 EUROPE: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 129

TABLE 52 ASIA PACIFIC: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 130

TABLE 53 LATIN AMERICA: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 130

TABLE 54 MIDDLE EAST: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 130

TABLE 55 GCC COUNTRIES: ENDOTOXIN TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 131

6.2.4 VIRUS SAFETY TESTING SERVICES 131

6.2.4.1 Rising focus on development of advanced therapies to drive growth 131

TABLE 56 VIRUS SAFETY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) 132

TABLE 57 NORTH AMERICA: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 132

TABLE 58 EUROPE: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 132

TABLE 59 ASIA PACIFIC: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 133

TABLE 60 LATIN AMERICA: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 133

TABLE 61 MIDDLE EAST: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 133

TABLE 62 GCC COUNTRIES: VIRUS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 134

6.2.5 BIOBURDEN TESTING SERVICES 134

6.2.5.1 Growing adoption of advanced testing solutions for contamination risk mitigation to propel growth 134

TABLE 63 BIOBURDEN TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION) 135

TABLE 64 NORTH AMERICA: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 135

TABLE 65 EUROPE: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 135

TABLE 66 ASIA PACIFIC: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 136

TABLE 67 LATIN AMERICA: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 136

TABLE 68 MIDDLE EAST: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 136

TABLE 69 GCC COUNTRIES: BIOBURDEN TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION) 137

6.2.6 OTHER BIOLOGICS SAFETY TESTING SERVICES 137

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 70	OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)	137
TABLE 71	NORTH AMERICA: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	138
TABLE 72	EUROPE: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	138
TABLE 73	ASIA PACIFIC: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	139
TABLE 74	LATIN AMERICA: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	139
TABLE 75	MIDDLE EAST: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	139
TABLE 76	GCC COUNTRIES: OTHER BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	140
6.3	CONSUMABLES	140
6.3.1	INCREASING DEMAND FOR HIGH-QUALITY ASSAYS AND REAGENTS TO DRIVE MARKET	140
TABLE 77	BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY REGION, 2022-2029 (USD MILLION)	141
TABLE 78	NORTH AMERICA: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	141
TABLE 79	EUROPE: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	141
TABLE 80	ASIA PACIFIC: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	142
TABLE 81	LATIN AMERICA: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	142
TABLE 82	MIDDLE EAST: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	142
TABLE 83	GCC COUNTRIES: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	143
6.4	INSTRUMENTS	143
6.4.1	RIISING ADOPTION OF ADVANCED TECHNOLOGIES TO SUPPORT MARKET GROWTH	143
TABLE 84	BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)	144
TABLE 85	NORTH AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	144
TABLE 86	EUROPE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	145
TABLE 87	ASIA PACIFIC: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	145
TABLE 88	LATIN AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	146
TABLE 89	MIDDLE EAST: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	146
TABLE 90	GCC COUNTRIES: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	146
7	BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE	147
7.1	INTRODUCTION	148
TABLE 91	BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)	148
7.2	RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS	148
7.2.1	STRINGENT REGULATORY GUIDELINES FOR BIOLOGIC DRUG MANUFACTURING TO PROPEL MARKET	148
TABLE 92	RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY REGION, 2022-2029 (USD MILLION)	149
TABLE 93	NORTH AMERICA: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	149
TABLE 94	EUROPE: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	150
TABLE 95	ASIA PACIFIC: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	150
TABLE 96	LATIN AMERICA: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	151
TABLE 97	MIDDLE EAST: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	151
TABLE 98	GCC COUNTRIES: RESIDUAL HOST CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	151
7.3	MYCOPLASMA TESTS	152
7.3.1	RIISING CONCERNS OF CELL CULTURE CONTAMINATION TO DRIVE MARKET	152
TABLE 99	MYCOPLASMA TESTS MARKET, BY REGION, 2022-2029 (USD MILLION)	152
TABLE 100	NORTH AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	153

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 101	EUROPE: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	153
TABLE 102	ASIA PACIFIC: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	153
TABLE 103	LATIN AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	154
TABLE 104	MIDDLE EAST: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	154
TABLE 105	GCC COUNTRIES: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	154
7.4	STERILITY TESTS	155
7.4.1	COMPULSORY STERILITY TESTING AT EACH STAGE IN DRUG DEVELOPMENT AND PRODUCTION PROCESS TO SUPPORT SEGMENT GROWTH	155
TABLE 106	STERILITY TESTS MARKET, BY REGION, 2022-2029 (USD MILLION)	155
TABLE 107	NORTH AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	156
TABLE 108	EUROPE: STERILITY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	156
TABLE 109	ASIA PACIFIC: STERILITY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	156
TABLE 110	LATIN AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	157
TABLE 111	MIDDLE EAST: STERILITY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	157
TABLE 112	GCC COUNTRIES: STERILITY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	157
7.5	ENDOTOXIN TESTS	158
7.5.1	INCREASING RESEARCH AND DEVELOPMENT FOR PRODUCTION OF BIOLOGICS TO DRIVE MARKET	158
TABLE 113	ENDOTOXIN TESTS MARKET, BY REGION, 2022-2029 (USD MILLION)	158
TABLE 114	NORTH AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	159
TABLE 115	EUROPE: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	159
TABLE 116	ASIA PACIFIC: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	159
TABLE 117	LATIN AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	160
TABLE 118	MIDDLE EAST: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	160
TABLE 119	GCC COUNTRIES: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	160
7.6	VIRUS SAFETY TESTS	161
7.6.1	GROWING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE SEGMENT GROWTH	161
TABLE 120	VIRUS SAFETY TESTS MARKET, BY REGION, 2022-2029 (USD MILLION)	161
TABLE 121	NORTH AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	162
TABLE 122	EUROPE: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	162
TABLE 123	ASIA PACIFIC: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	162
TABLE 124	LATIN AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	163
TABLE 125	MIDDLE EAST: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	163
TABLE 126	GCC COUNTRIES: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	163
7.7	BIOBURDEN TESTS	164
7.7.1	GROWING STRINGENCY OF DRUG SAFETY STANDARDS TO INCREASE DEMAND FOR MICROBIOLOGICAL BIOBURDEN TESTING	164
TABLE 127	BIOBURDEN TESTS MARKET, BY REGION, 2022-2029 (USD MILLION)	164
TABLE 128	NORTH AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	165
TABLE 129	EUROPE: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	165
TABLE 130	ASIA PACIFIC: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	165
TABLE 131	LATIN AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	166
TABLE 132	MIDDLE EAST: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	166
TABLE 133	GCC COUNTRIES: BIOBURDEN TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	166
7.8	OTHER BIOLOGICS SAFETY TESTS	166
TABLE 134	OTHER BIOLOGICS SAFETY TESTS MARKET, BY REGION, 2022-2029 (USD MILLION)	167
TABLE 135	NORTH AMERICA: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	167
TABLE 136	EUROPE: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	168

TABLE 137	ASIA PACIFIC: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	168
TABLE 138	LATIN AMERICA: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	169
TABLE 139	MIDDLE EAST: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	169
TABLE 140	GCC COUNTRIES: OTHER BIOLOGICS SAFETY TESTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	169
8	BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION	170
8.1	INTRODUCTION	171
TABLE 141	BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)	171
8.2	MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING	171
8.2.1	GROWING REGULATORY APPROVALS FOR MONOCLONAL ANTIBODIES TO SUPPORT MARKET GROWTH	171
TABLE 142	BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)	172
TABLE 143	NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	172
TABLE 144	EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	173
TABLE 145	ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	173
TABLE 146	LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	174
TABLE 147	MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)	174
TABLE 148	GCC: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	174
8.3	VACCINES DEVELOPMENT AND MANUFACTURING	175
8.3.1	RIISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE GROWTH	175
TABLE 149	BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)	176
TABLE 150	NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	176
TABLE 151	EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	176
TABLE 152	ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	177
TABLE 153	LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	177
TABLE 154	MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)	177
TABLE 155	GCC: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	178
8.4	CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING	178
8.4.1	INCREASING INVESTMENTS FOR DEVELOPMENT OF CELLULAR & GENE THERAPIES TO DRIVE GROWTH	178
TABLE 156	BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)	179
TABLE 157	NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	179
TABLE 158	EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	180

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 159	ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	180
TABLE 160	LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	181
TABLE 161	MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)	181
TABLE 162	GCC: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	181
8.5	BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING	182
8.5.1	GROWING DEMAND FOR BLOOD PRODUCTS TO PROPEL GROWTH	182
TABLE 163	BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)	182
TABLE 164	NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	183
TABLE 165	EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	183
TABLE 166	ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	184
TABLE 167	LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	184
TABLE 168	MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY REGION, 2022-2029 (USD MILLION)	184
TABLE 169	GCC: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS DEVELOPMENT AND MANUFACTURING, BY COUNTRY, 2022-2029 (USD MILLION)	185
8.6	OTHER APPLICATIONS	185
TABLE 170	BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)	186
TABLE 171	NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	186
TABLE 172	EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	186
TABLE 173	ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	187
TABLE 174	LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	187
TABLE 175	MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)	187
TABLE 176	GCC: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)	188
9	BIOLOGICS SAFETY TESTING MARKET, BY END USER	189
9.1	INTRODUCTION	190
TABLE 177	BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)	190
9.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	190
9.2.1	INCREASING PHARMACEUTICAL R&D SPENDING AND GROWING STRATEGIC ALLIANCES TO DRIVE GROWTH	190
FIGURE 32	GLOBAL PHARMACEUTICAL R&D SPENDING, 2014-2028 (USD BILLION)	191
TABLE 178	BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)	191
TABLE 179	NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)	192

TABLE 180	EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)	192
TABLE 181	ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)	192
TABLE 182	LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)	193
TABLE 183	MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)	193
TABLE 184	GCC: BIOLOGICS SAFETY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)	193
9.3	CROS & CDMOS	194
9.3.1	INCREASING FOCUS ON EXPANSION OF CROS AND CDMOS TO PROPEL GROWTH	194
TABLE 185	BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY REGION, 2022-2029 (USD MILLION)	194
TABLE 186	NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022-2029 (USD MILLION)	195
TABLE 187	EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022-2029 (USD MILLION)	195
TABLE 188	ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022-2029 (USD MILLION)	196
TABLE 189	LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022-2029 (USD MILLION)	196
TABLE 190	MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY REGION, 2022-2029 (USD MILLION)	196
TABLE 191	GCC: BIOLOGICS SAFETY TESTING MARKET FOR CROS & CDMOS, BY COUNTRY, 2022-2029 (USD MILLION)	197
9.4	ACADEMIC & RESEARCH INSTITUTES	197
9.4.1	SURGE IN R&D ACTIVITIES FOR DEVELOPMENT OF ADVANCED THERAPIES TO BOOST MARKET GROWTH	197
TABLE 192	BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)	198
TABLE 193	NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)	198
TABLE 194	EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)	198
TABLE 195	ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)	199
TABLE 196	LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)	199
TABLE 197	MIDDLE EAST: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)	199
TABLE 198	GCC: BIOLOGICS SAFETY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)	200
10	BIOLOGICS SAFETY TESTING MARKET, BY REGION	201
10.1	INTRODUCTION	202
TABLE 199	BIOLOGICS SAFETY TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)	202
10.2	NORTH AMERICA	202
FIGURE 33	NUMBER OF BIOSIMILARS APPROVED ANNUALLY BY US FDA, 2015 TO 2023	203
10.2.1	NORTH AMERICA: RECESSION IMPACT	203
FIGURE 34	NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET SNAPSHOT	204
TABLE 200	NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)	204
TABLE 201	NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)	205
TABLE 202	NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)	205

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 203NORTH AMERICA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)206

TABLE 204NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)206

TABLE 205NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)207

10.2.2US207

10.2.2.1Increasing investments in biotechnology industry to drive market growth207

FIGURE 35TOTAL US NIH BIOTECHNOLOGY FUNDING, FY 2013 TO FY 2024208

TABLE 206US: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)208

TABLE 207US: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)209

TABLE 208US: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)209

TABLE 209US: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)210

TABLE 210US: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)210

10.2.3CANADA210

10.2.3.1Investments for expanding biomanufacturing capacity to propel market growth210

TABLE 211CANADA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)211

TABLE 212CANADA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY TYPE, 2022-2029 (USD MILLION)211

TABLE 213CANADA: BIOLOGICS SAFETY TESTING PRODUCTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)212

TABLE 214CANADA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)212

TABLE 215CANADA: BIOLOGICS SAFETY TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)213

Biologics Safety Testing Market by Product & Service (Consumables, Instrument, Services), Test Type (Mycoplasma, Sterility, Endotoxin, Bioburden, Virus Safety), Application (Vaccines, mAbs, Cell & Gene Therapy, Blood Products) - Global Forecast to 2029

Market Report | 2024-05-13 | 387 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature